Received Nov 6, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RSV | RSV (AREXVY) | GLAXOSMITHKLINE BIOLOGICALS | UNK | UNK | — |
she has had a non-stop cough; This non-serious case was reported by a consumer via call center representative and described the occurrence of cough in a female patient who received RSVPreF3 adjuvanted (Arexvy) for prophylaxis. In OCT-2025, the patient received Arexvy. In OCT-2025, less than 2 weeks after receiving Arexvy, the patient experienced cough (Verbatim: she has had a non-stop cough). The outcome of the cough was not resolved. It was unknown if the reporter considered the cough to be related to Arexvy. It was unknown if the company considered the cough to be related to Arexvy. Additional Information: GSK Receipt Date: 22-OCT-2025 The reporter was a consumer who stated that she had received an injection of Arexvy approximately two weeks prior to reporting the event. Following the vaccination, she experienced a persistent, non-stop cough that lasted for two weeks. No additional information was provided during the report. The batch number was not provided, and we are unable to contact the reporter.